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Abstract: Kynurenines are the products of tryptophan metabolism. Among them, 
kynurenine and kynurenic acid are generally thought to have neuroprotective properties, 
while 3-hydroxykynurenine, 3-hydroxyanthranilic acid and quinolinic acid are considered 
neurotoxic. They participate in immunoregulation and inflammation and possess pro- or  
anti-excitotoxic properties, and their involvement in oxidative stress has also been  
suggested. Consequently, it is not surprising that kynurenines have been closely related to 
neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease, amyotrophic lateral sclerosis and multiple sclerosis. More information about the 
less-known metabolites, picolinic and cinnabarinic acid, evaluation of new receptorial 
targets, such as aryl-hydrocarbon receptors, and intensive research on the field of the 
immunomodulatory function of kynurenines delineated the high importance of this 
pathway in general homeostasis. Emerging knowledge about the kynurenine pathway 
provides new target points for the development of therapeutical solutions against 
neurodegenerative diseases. 
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1. Introduction 
Nowadays, the interpretation of neurotoxicity is not confined to the idea of external substances 
causing neuronal damage. Basically, every substance or phenomenon, whether it is internal or external, 
causing damage to the neurons is considered neurotoxic. 
Neurodegenerative diseases, such as Parkinson’s disease (PD), Alzheimer’s disease (AD), 
Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), etc., all possess 
characteristics related to neurotoxic processes. Consequently, neurodegeneration in general could be 
attributable to various forms of neurotoxicity. Neurodegenerative diseases have different courses and 
distinct clinical symptoms; however, they share some common mechanisms, which eventually lead to 
neuronal death. These processes are the imbalance in intracellular energy homeostasis, excitotoxicity 
and inflammation [1–3]. A long line of evidence proves that the kynurenine pathway (KP) of 
tryptophan (TRP) metabolism and the pathomechanism of neurodegenerative diseases are associated at 
several points [4]. This review will focus on the properties of kynurenine metabolites related to 
neurotoxicity also occurring in neurodegenerative diseases. 
2. Common Neurotoxic Mechanisms in Neurodegeneration 
The neural tissue is the main energy consumer of the human body, and imbalance in energy 
homeostasis can lead to neuronal deficit and, eventually, to neuronal death. The energy, in the form of 
ATP, is provided by the mitochondria. These organelles are the scenes of the citric acid cycle, fatty 
acid oxidation, the urea cycle and oxidative phosphorylation. Impaired mitochondrial function  
leads to energy deficit (lack of ATP), which, in turn, leads to the disruption of Na+/K+-ATP-ase,  
Ca2+/H+-ATP-ase and the reversion of the Na+/Ca2+ transporter [5]. Under these circumstances, the 
cells are not able to maintain their normal membrane potential, resulting in depolarization. Cells with 
disrupted membrane potential are more prone to excitotoxic and oxidative damage [6]. 
Furthermore, impaired mitochondrial function causes the uncontrolled generation of reactive 
oxygen (ROS) and nitrogen species (RNS): superoxide anion (O2•−), hydroxyl radical (•OH), hydrogen 
peroxide (H2O2), nitric oxide (•NO), nitrogen dioxide (•NO2) and peroxynitrite anion (ONOO−).  
ROS and RNS can attack macromolecules, resulting in misfolded proteins, lipid peroxidation or 
nitrosylation and nucleic acid damage. However, mitochondria are not the only source of ROS in  
the cells; peroxisomes and the endoplasmic reticulum are also capable of ROS production. Besides, 
numerous enzymes are known to produce ROS, too, e.g., NADPH oxidases, cyclooxygenases, 
xanthine oxidase, cytochrome P450 enzymes and nitrogen oxide synthases [7]. The excess amount of 
reactive species, i.e., oxidative stress, is closely related to neurodegenerative diseases. 
ROS can also originate from microglia, which are likely to contribute to the degenerative course 
after activation. Microglia are the resident immune cells of the central nervous system (CNS), 
providing defense against external pathogens and pollutants and clearing of cellular debris. Activated 
microglia are present in diseased brains [8–10], indicating the contribution of inflammatory processes 
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to neurodegeneration [11,12]. Chronic neuroinflammation, prolonged activation of microglia and 
astrocytes and persistent exposure to inflammatory cytokines are considered neurotoxic. 
Excitotoxicity is the neuronal death caused by excessive or prolonged activation of excitatory amino 
acid receptors. The main participant in this process is glutamate, acting on ionotropic N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) and kainate receptors and 
on metabotropic glutamate receptors [3]. An excessive amount of glutamate in the synaptic cleft can 
result in the dysregulation of Ca2+ homeostasis, mitochondrial dysfunction and the generation of ROS 
and RNS. Under normal conditions, the presence and amount of glutamate is highly regulated, but in 
neurodegenerative diseases, this regulation is often disrupted, contributing to neuronal damage. 
The mechanisms detailed above are in close relation in the development of neurodegenerative 
diseases [13–15] (Figure 1); however, their level of contribution to the pathological phenomena varies 
among the different disorders. 
 
Figure 1. Schematic drawing of the common neurotoxic mechanisms in neurodegeneration. 
The figure attempts to interpret that the involvement and interrelationship of metabolic 
disturbances, neuroinflammation and excitotoxicity causes neurotoxicity that eventually 
results in neurodegeneration. 
3. The Kynurenine Pathway 
The main route of TRP metabolism is the kynurenine pathway (KP) (Figure 2), yielding neuroactive 
metabolites and nicotinamide adenine dinucleotide (NAD+). More than 95% of TRP is metabolized 
through the KP [16], while the remaining TRP is metabolized by the serotonin pathway. 
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Figure 2. The kynurenine pathway. The metabolism of L-tryptophan is divided into  
two distinct pathways, the serotonin and the kynurenine pathway (KP). Indoleamine  
2,3-dioxygenase 1 and 2 and tryptophan 2,3-dioxygenase convert L-tryptophan to  
N-formyl-L-kynurenine in the first step of the KP. N-formyl-L-kynurenine is further 
processed by formamidase to L-kynurenine (L-KYN), the central metabolite of the KP. 
From L-KYN, three different enzymes produce the next metabolites, forming three 
branches of the metabolism. The first branch is the kynurenic acid branch, where 
kynurenine aminotransferases (KATs) produce kynurenic acid from L-KYN. On the second 
branch, kynureninase converts L-KYN to anthranilic acid, which is further metabolized by 
anthranilate 3-monoxygenase to 3-hydroxyanthranilic acid (3-HA). On the third branch, 
kynurenine monooxygenase produces 3-hydroxykynurenine (3-HK), which is further 
metabolized by kynureninase to 3-HA. 3-HK can be also metabolized by KATs to form 
xanthurenic acid or be auto-oxidized. 3-HA is converted by 3-hydroxyanthranilic acid 
oxygenase to 2-amino-3-carboxymuconate semialdehyde or suffers auto-oxidation to  
form cinnabarinic acid. 2-amino-3-carboxymuconate semialdehyde can be converted by 
picolinic carboxylase to picolinic acid or can be converted by non-enzymatic cyclisation to 
quinolinic acid, which, through conversion by quinolinic acid phosphoribosyltransferase, 
results in the formation of nicotinamide adenine dinucleotide. 
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In the first step of the KP, TRP is converted to N-formyl-L-kynurenine, an instable compound, by 
the enzymes tryptophan 2,3-dioxygenase (TDO) and indoleamine 2,3-dioxygenase 1 and 2 (IDO1, IDO2). 
These enzymes are the main rate limiting enzymes of the KP. Interferon-α, interferon-β (IFN-β) and 
interferon-γ (IFN-γ) are all able to induce IDO [17,18], but IFN-γ is considered as the main activator of 
IDO [19]. Furthermore, tumor necrosis factor-α and interleukin-6 are also able to activate IDO in an 
IFN-γ-independent way [20]. Previous investigations also showed that IDO has an important role in 
maternal-fetal tolerance, and both enzymes bear immunosuppressive properties [21,22]. 
N-formyl-L-kynurenine is further degraded by formamidase to L-kynurenine (L-KYN). L-KYN was 
long thought not to have neuroactive properties. L-KYN participation in oxidative processes has been 
proposed; pro-and also anti-oxidative properties have been documented [23]. 
Recently, evidence emerged that L-KYN is an endogenous ligand for the human aryl-hydrocarbon 
receptor (AHR) (Table 1) [24]. This receptor has an important role in cellular responses evoked by 
environmental toxins, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin [25] and polycyclic aromatic 
hydrocarbons [26–28]. The AHR is a ligand-activated transcription factor, a member of the family of 
basic helix-loop-helix transcription factors [29]. It is a cytosolic protein that is normally inactive,  
but after ligand binding, it translocates to the nucleus, where it binds to the regulatory regions of 
xenobiotic-responsive elements. DNA binding indicates diverse transcriptional responses, such as  
the activation of enzymes participating in xenobiotic metabolism. AHR also participates in immune  
response [30,31] and in tumor genesis [32]. Besides environmental pollutants, numerous endogenous 
AHR ligands have been identified, including kynurenines L-KYN and kynurenic acid (KYNA) [33], 
suggesting the involvement of the KP in the diverse transcriptional pathways, regulated by AHR. 
In the CNS, 40% of L-KYN is generated locally, and 60% is taken up from the blood [34]. The KP 
continues in different branches deriving from L-KYN, the first one leading to the synthesis of KYNA 
by kynurenine aminotransferases (KATs). KYNA is present in the human and rat brain in nanomolar 
concentrations [35], and it is an endogenous broad-spectrum antagonist of NMDA receptors acting at 
low concentrations on the strychnine-insensitive glycine site [36], while at higher concentrations on 
the glutamate recognition site (Table 1) [37]. Furthermore, it is a weak antagonist of kainate and 
AMPA ionotropic glutamate receptors [38]. At low concentrations (nM–μM), KYNA has a facilitatory 
effect on AMPA receptors, while at higher concentrations, it acts as a competitive antagonist [39,40].  
The broad spectrum of KYNA’s receptorial action is in favor of its important role in regulation of 
glutamatergic neurotransmission. 
On α7-nicotinic acetylcholine receptors (α7nAch), KYNA exerts a non-competitive antagonistic 
effect [41], thus participating in both glutamatergic and nicotinergic neurotransmission. Modulation of 
α7nAch, thus presynaptic glutamate release by KYNA, seems to be an important site of action in 
protection against glutamate induced excitotoxicity. KYNA has been proposed as an endogenous 
agonist of the G-protein coupled receptor 35 (GPR35) [42], the function of which is yet poorly 
elucidated. GPR35 is expressed in the gastro-intestinal system and in immune cells [42], but it is functional 
in dorsal root ganglia and also in hippocampal neurons [43,44]. It also has been demonstrated, that 
KYNA, similarly to L-KYN, is a ligand to AHR [33]. The effects of KYNA on GPR35 and AHR 
suggest an important immunomodulatory role for this compound. Recently, it was shown that KYNA 
is able to scavenge ROS in an NMDA- and nicotinic receptor-independent way; thus, it can be  
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a potential endogenous antioxidant [45]. Taken together, KYNA is involved in possible neurotoxic 
processes as a protective agent, underlining its importance in neurodegenerative mechanisms. 
The second branch of the KP deriving from L-KYN proceeds to anthranilic acid (AA) with the  
aid of kynureninase. AA has been shown to inhibit citric acid cycle and the respiratory chain  
complexes I–III [46], interfering with mitochondrial function. It may have an anti-inflammatory effect 
by forming a complex with copper and acting as an •OH inactivating ligand [47,48]. Anthranilate  
3-monooxygenase converts AA to 3-hydroxyanthranilic acid (3-HA), thus rallying to the third branch 
of L-KYN metabolism. 
The first step of the third branch is the conversion of L-KYN by kynurenine monooxygenase 
(KMO) to 3-hydroxykynurenine (3-HK). KMO has the highest affinity for L-KYN among the enzymes 
of the three branches, suggesting that under physiological conditions, L-KYN is metabolized by this 
third branch [49]. 3-HK undergoes auto-oxidation, forming highly reactive o-aminoquinone and 
ROS—O2•− and H2O2 [50–53]—and dimerizes to hydroxanthommatin and xanthommatin under 
physiological conditions [51,53]. 3-HK is generally considered as a neurotoxic agent in vivo, causing 
convulsive attacks when administered intraventricularly [54] or leading to tissue damage when 
administered intrastriatally [55]. 3-HK is also present in eye lens, and it has been connected with  
cataract formation [56]. 
The toxicity of 3-HK can be attributable to its capability to produce free radicals during its  
auto-oxidation. However, the free radical scavenging effects of this compound have also been 
observed in vitro in rat cortex and in C6 glioma cells [57]. Pro- or anti-oxidative properties of 3-HK 
under different circumstances were thoroughly reviewed by Colín-Gonzalez and colleagues [58]. 
The next step in the metabolism of L-KYN is the generation of 3-HA from either 3-HK by 
kynureninase or from AA by anthranilate 3-monooxygenase. 3-HA is also prone to auto-oxidation, 
generating superoxide radicals, H2O2, and cinnabarinic acid [59]. Cinnabarinic acid is a ligand for  
the type 4 metabotropic glutamate receptor and also for AHR [60,61]. 3-HA can induce apoptosis  
in monocytes/macrophages [62], and it can inhibit the mitochondrial respiratory chain [46,63]. 
Furthermore, it has important immunoregulatory functions by interfering with T-cell survival [64]. 
3-HK also can be transaminated by KAT to xanthurenic acid, which, similarly to 3-HK and 3-HA, 
possesses both pro- and anti-oxidative properties [65–67]. 
3-HA is further processed by 3-hydroxyanthranillic acid oxygenase (3-HAO) to 2-amino-3-
carboxymuconate semialdehyde. This intermediate can be metabolized by picolinic carboxylase to 
produce picolinic acid (PIC) or can be transformed by nonenzymatic cyclisation to quinolinic  
acid (QUIN). 
PIC is a non-selective metal ion chelating agent [68], induces morphological changes in the rat 
hippocampus, substantia nigra and striatum when administered intraperitoneally [69] and has a 
macrophage induction activity [70]. PIC is able to prevent QUIN-induced neurotoxicity when injected 
into the nucleus basalis magnocellularis of the rat [71], and it is able to modulate kainate-induced 
glutamate release from the striatum [72]. 
QUIN under normal conditions is present in the brain in nanomolar concentrations and metabolized 
for the synthesis of NAD+. In vitro, QUIN is toxic for brain cells from above 150 nM [73]. QUIN is  
a weak endogenous agonist on NMDA receptors [74], the action of which is selective, involving the 
receptor subtypes containing the NR2A and NR2B subunits [75]. QUIN causes the greatest excitotoxic 
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damage in brain areas rich in NMDA receptors containing NR2A and NR2B subunits, mainly in the 
striatum and in the hippocampus [76]. Furthermore, it can increase glutamate release by neurons and 
inhibit glutamate uptake by astrocytes, maintaining an elevated level to constantly stimulate NMDA 
receptors, resulting in excitotoxicity [77]. Lipid peroxidation also contributes to QUIN toxicity [78];  
results suggest that QUIN forms a complex with iron, and this complex can contribute to the  
formation of ROS [79,80]. The toxicity of QUIN on brain cells is exerted mainly through  
NMDA-mediated excitotoxicity [73,81]. 
Table 1. Short summary of the direct receptorial effects of kynurenine pathway metabolites. 
Kynurenine Pathway Metabolite Receptorial Effect References 
L-Kynurenine Aryl hydrocarbon receptor (AHR) agonist [24] 
Kynurenic acid 
NMDA receptor antagonist [36,37] 
Dual effect on AMPA receptors: partial agonist at 
low nanomolar concentrations; antagonist at high 
micromolar-millimolar concentrations 
[39,40] 
Kainate receptor antagonist [38] 
α7-nicotinic acetylcholine receptor antagonist [41] 
G-protein coupled receptor 35 agonist [42] 
AHR agonist [33] 
Cinnabarinic acid 
Type 4 metabotropic glutamate receptor agonist [60] 
AHR agonist [61] 
Quinolinic acid NMDA agonist [74] 
NMDA: N-methyl-D-aspartate; AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid. 
Quinolinic acid phosphoribosyltransferase converts QUIN to NAD+, finishing the metabolic 
process. NAD+ is thereafter utilized by different intracellular processes, serving as an electron  
transfer molecule. 
The enzymes of the KP are differently distributed among the various cell types in the CNS, 
providing an important way of controlling the synthesis of different metabolites. Macrophages and 
microglia express the entire enzymatic machinery of the KP [82–84], and neurons are able to 
synthesize KYNA [85] and PIC [86], while astrocytes lack the enzyme KMO; therefore, they are not 
able to synthesize 3-HK under physiological conditions [83]. 
4. Kynurenines in Neurodegenerative Diseases 
4.1. Alzheimer’s Disease 
Alzheimer’s disease is characterized by progressive cognitive decline and memory loss, mainly in 
the elderly population. Pathological protein aggregates in the form of amyloid β (Aβ)-formed plaques, 
and phosphorylated tau (p-tau)-constituted neurofibrillary tangles are the main hallmarks of the 
disorder. An increased L-KYN/TRP ratio in AD patients suggests an enhanced TRP metabolism and  
the increased activation of IDO, which could be connected to neuroinflammation being activated by 
IFN-γ [87]. 3-HK levels are increased in peripheral blood of AD patients compared to controls [88], further 
supporting a metabolic shift in diseased patients. Furthermore, results showed that QUIN accumulates 
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in the brain of AD patients, and it is co-localized with p-tau and neurofibrillary tangles [89,90].  
Levels of KYNA are also elevated in AD patients, mainly in the striatum and in the hippocampus [91]. 
These result suggest that the kynurenine pathway in general is upregulated in AD, but the origin of this 
phenomenon needs further clarification. Activated microglia may produce an increased amount of KP 
metabolites in response to Aβ and p-tau, and it is possible that the excess amount of the produced 
QUIN leads to the invigoration of tau phosphorylation and to the development of a vicious circle [90]. 
4.2. Parkinson’s Disease 
Parkinson’s disease is the second most prevalent neurodegenerative disease, characterized by 
pathological presence of Lewy bodies and Lewy neurites, comprised mainly of α-synuclein, in the 
neuromelanin-containing dopaminergic cells. Selective death of dopaminergic neurons is most 
abundant in the substantia nigra pars compacta; however, expansive neurodegeneration is present in 
the CNS [92]. The selective degradation of the nigrostriatal pathway leads to the motor symptoms 
characteristic of PD. Oxidative stress, excitotoxicity and neuroinflammation can both be significant 
factors in the selective death of dopaminergic cells [93,94]. The involvement of the KP in PD has been 
investigated in several studies. Widner and colleagues found an increased L-KYN/TRP ratio in serum 
and cerebrospinal fluid (CSF) of PD patients [95], while Ogawa and co-workers demonstrated 
decreased L-KYN and KYNA and increased 3-HK levels in brain samples of PD patients [96]. These 
result suggest the upregulation of TRP metabolism in PD, further supported by the finding that 3-HK 
levels increased in CSF [97]. 
4.3. Huntington’s Disease 
Huntington’s disease is an autosomal dominantly inherited disorder caused by the CAG expansion 
in the HD gene on chromosome 4. This gene encodes the protein huntingtin, the normal functions of 
which are still under intensive research. The disease presents with motor symptoms and progressive 
cognitive decline. Excitotoxicity is considered as one of the main factors in the disease. 
Administration of QUIN can serve as an animal model of HD, because it causes lesions 
pathologically similar to that of human samples, as it spares the cholinergic and aspiny neurons of the 
striatum [98]. Based on these observations, the quinolinate hypothesis of HD emerged, suggesting that 
QUIN may have a causative role in this disease. Several studies measured the levels of the KP 
metabolites, especially QUIN, in brain and CSF in postmortem samples of HD patients. Brain tissue 
levels of QUIN were found to be reduced [99]; also, the levels of KYNA were found to be decreased 
both in CSF and brain in HD [100–103], while an increase in 3-HK levels was found [104]. Measuring 
the same compounds during the early stages of HD revealed that both 3-HK and QUIN are elevated, 
while at later stages, no change or a decrease can be observed [105]. These results suggest that 3-HK 
and QUIN may be participants in the degenerative processes early in the course of HD. 
4.4. Amyotrophic Lateral Sclerosis 
ALS is a progressive neurodegenerative disorder, affecting motor neurons at both spinal, brainstem 
and cortical levels. ALS is mainly sporadic, with a 5%–10% occurrence of familial cases, affecting the 
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adult population. About 20% of the familial cases is attributable to the mutation of the superoxide 
dismutase 1 (SOD1) gene [106], coding an important free radical scavenging enzyme. The symptoms 
include muscle weakness, atrophy and paralysis, and in most cases, the involvement of breathing 
muscles results in death within 3–5 years from disease onset. 
Perturbations of the kynurenines in ALS were studied by several groups, Chen and colleagues  
found increased L-KYN and QUIN levels in CSF and serum of ALS patients [107], while KYNA 
levels were elevated in CSF of bulbar onset patients, but decreased in the serum of patients with severe  
clinical status [108]. 
The exact pathomechanism of ALS is not understood, but the general view is that it is  
a multifactorial disease, involving glutamate excitotoxicity, mitochondrial dysfunction, oxidative  
stress and inflammation. The kynurenines are involved in all of the above-mentioned processes, thus 
providing a multitarget option for therapeutic intervention in ALS. 
4.5. Multiple Sclerosis 
Demyelinization and the forming of sclerotic plaques are the most well-known characteristic of MS. 
The loss of the myelin sheath and the inflammation at different sites of the CNS causes diverse 
symptoms and distinct disease courses in MS. MS can be categorized based on the disease course as 
clinically-isolated syndrome, relapsing-remitting MS, primary progressive MS, secondary progressive 
MS and progressive relapsing MS. 
Alterations in the KP were noted in MS; levels of TRP were found to be reduced both in the CSF 
and plasma of MS patients compared with control subjects [109,110]. Furthermore, KYNA levels were 
shown to be significantly decreased in CSF of MS patients during remission, while a significant 
increase is present both in the plasma and CSF in the course of relapse [111–113]. These findings 
suggest that levels of KYNA may be directly involved in the alternation of relapsing-remitting phases 
of the disease. 
IFN-β treatment, a first line therapy applied in MS, has been shown to significantly increase  
L-KYN levels and the L-KYN/TRP ration, which is indicative of IDO activity. These results suggest 
that IFN-β treatment leads to the induction of IDO [114,115]; thus, the important role of IDO and the 
KP in immune response and autoimmunity is further confirmed (thoroughly reviewed in [4,116]). 
4.6. Acquired Immunodeficiency Syndrome Dementia Complex 
Infection with human immunodeficiency virus type 1 (HIV-1) can lead to the development of 
acquired immunodeficiency syndrome dementia complex (ADC), also termed HIV-associated 
dementia. ADC is a subcortical type of dementia characterized by marked memory impairment and 
psychomotor slowing. It occurs in the severe forms of HIV-1 infection, affecting about 2% of the 
infected population receiving combined antiretroviral therapy, as demonstrated by the CHARTER 
study [117]. Heyes and colleagues proposed that QUIN could play a direct role in the development of 
ADC, as QUIN levels were elevated in HIV-infected patients and correlated with the severity of 
neurological deficits [118]. A more feasible hypothesis suggests that QUIN is elevated due to the 
inflammatory process generated by HIV-1, nevertheless emphasizing the importance of the KP in 
inflammatory processes [119]. 
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5. Therapeutic Perspectives 
Neurodegenerative diseases are a great socio-economic burden, and in most cases, the therapies 
available provide only symptomatic relief; they do not treat the cause of the disorders. Consequently, 
there is a constant need for new and effective therapeutic solutions. Manipulating the KP could result 
in beneficial effects, affecting each of the contributory mechanisms of neuroinflammation, oxidative 
stress and excitotoxicity. 
One of the possible beneficiary therapeutic interventions is the shifting of KP metabolism towards 
the formation of protective agents, mainly KYNA (Table 2). This metabolic shift can be achieved  
by specific enzyme inhibitors of KMO, kynureninase and 3-HAO. Several compounds have been 
developed for the inhibition of these enzymes [120–122], but the inhibitors of KMO have been the 
most widely studied and may provide the most beneficial effects, because inhibition of KMO prevents 
the formation of the most neurotoxic kynurenines, 3-HK, 3-HAA and QUIN. 
Table 2. Therapeutic options for modulating the kynurenine pathway in neurodegenerative 
diseases, with some of the candidates developed and tested so far. 
Enzyme Inhibitors Kynurenic Acid Prodrugs or Analogs 
3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl] 
benzenesulfonamide (Ro-61-8048) 
L-Kynurenine 
2-(3,4-dimethoxybenzenesulfonylamino)-4- 
(3-nitrophenyl)-5-(piperidin-1-yl)methylthiazole (JM6) 
Combination of L-kynurenine and probenecid  
N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-
quinoline-2-carboxamide hydrochloride 
nicotinylalanine 
7-Chlorokynurenic acid 
4-Chlorokynurenine (AV-101) 
Inhibition of KMO leads to a decrease in the levels of 3-HK and QUIN in rats [123]. Blockade with 
3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro-61-8048), a potent KMO 
inhibitor, results in increased KYNA content in parkinsonian monkeys, and when combined with 
levodopa, it reduces the severity of dyskinesias, both acutely and after prolonged administration [124,125]. 
A prodrug of Ro-61-8048, 2-(3,4-dimethoxybenzenesulfonylamino)-4-(3-nitrophenyl)-5-(piperidin-1-yl) 
methylthiazole (JM6), was able to ameliorate anxiety-related behavior, spatial memory deficits and 
synaptic loss in a transgenic mouse model of AD and was able to decrease microglial activation and 
extend life span of R6/2 mice (a genetic mouse model of HD) [126]. However, the true prodrug 
properties of JM6 were questioned, and there is no doubt that Ro-61-8048 is an effective KMO 
inhibitor [127]. 
Another possibility for therapeutic intervention is the pharmacological increase of KYNA’s effect, 
either by administration of its prodrug or by synthetic analogs. 
Combined administration of L-KYN and probenecid (PROB), an inhibitor of organic anion 
transport, causes elevation in the cortical levels of KYNA [128]. The same combination was shown to 
reduce the toxic effects of 6-hydroxydopamine, a widely-used model of PD in rats; joint administration 
was able to mitigate rotation behavior and neurodegeneration [129]. L-KYN administered together 
with PROB was able to attenuate histopathological changes and improve spatial memory in the Aβ 
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model of AD [130]. Furthermore, L-KYN alone mitigated the neuronal cell loss and damage after 
ischemic insult in rats [131,132]. 
A combination of enzyme inhibition and pharmacological supplementation of KYNA also proved to 
be protective in a model of PD. L-KYN and PROB were combined with nicotinylalanine, an inhibitor 
of kynureninase and KMO, and were able to modulate QUIN-induced turning behavior [133]. 
During the past few years, several types of KYNA analogs have been synthesized (Scheme 1).  
A novel KYNA amide, N-(2-N,N-dimethylaminoethyl)-4-oxo-1H-quinoline-2-carboxamide hydrochloride, 
exerted beneficial effects in numerous paradigms. In micromolar concentrations, it reduced the 
amplitude of field excitatory postsynaptic potentials in the CA1 region of the hippocampus, while in 
nanomolar concentrations, it exerted a facilitatory effect, similar to KYNA [134]. In a transgenic 
mouse model of HD, the same analog increased survival time and prevented weight loss and striatal 
neuron loss of the animals [135]. The tests of the anti-inflammatory properties of this compound 
showed that it has a higher potency to inhibit tumor necrosis factor-α production than KYNA, 
suggesting a more potent immunoregulatory effect [136]. Similarly to KYNA, it also possesses 
protective characteristics against ischemia-induced neuronal loss [137]. The exact mechanism of action of 
this new compound is not known, but the lack of cognitive side effects makes it a promising candidate 
for further investigations [138]. 
 
Scheme 1. Transformational possibilities to develop kynurenic acid analogues. The 
transformations of kynurenic acid (KYNA) derivatives can be achieved through modification 
of the aromatic ring, the synthetically active 4-OH group, conversion of the 2-carboxylic 
function to pharmacologically interesting ester or amide derivatives of KYNA [139]. The 
amides of KYNA are pharmacologically and synthetically highly promising synthons in the 
patent literature. Coupling between KYNA and 2-dimethylaminoethylamine was achieved 
by using N,N'-diisopropylcarbodiimide (DCI) in the presence of 1-hydroxybenzotriazole 
hydrate (1-HOBT), yielding 2. Further transformations are also shown in Scheme 1 [140]. 
Halogenated KYNA analogues have also been tested; 7-chlorokynurenic acid is a selective 
antagonist of the glycine site of NMDA receptors [141], and it was able to modulate kainate-induced 
neurodegenerative changes [142,143]. However, the blood-brain barrier permeability of this drug is  
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not optimal; therefore, its prodrug, 4-chlorokynurenine (also known as AV-101), was examined and 
has been shown to be protective against QUIN neurotoxicity [143]. AV-101 has successfully 
completed a phase I clinical trial for the evaluation of safety, tolerability and pharmacokinetic profile 
(ClinicalTrials.gov Identifier: NCT01483846) and hopefully will be further processed. 
In summary, the interventions affecting the KP are promising targets in the development of 
neuroprotective strategies. 
6. Conclusions 
The KP is an important target for the development of new therapies against neurodegenerative 
disorders, as it is comprised of compounds influencing processes related to excitotoxicity, oxidative 
damage and inflammation. Compiling evidence suggests that the interplay between the immune and 
nervous system in neurodegeneration could be the main target of both diagnostic and therapeutic 
developments. Therefore, further characterization of the role of KP metabolites in the immune and 
nervous system could be the key to new pharmaceutical therapies. However, owing to the broad effects 
of certain KP metabolites, a more complex approach would be necessary to develop drugs with the 
fewest side effects. 
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